BioSpace News Archive

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company will present additional data from the APOLLO-B Phase 3 study of patisiran.

Thermo Fisher Scientific partners with the Taiwan Precision Medicine Initiative (TPMI) to advance the next phase of the large-scale predictive genomics study and support its goal of genotyping 1 million people in Taiwan.

Potrero Medical announced today that the FDA granted Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in cardiac post-surgical intensive care patients.

Ideon Technologies, a global pioneer in high-resolution subsurface imaging for the mining industry, announced it closed a US$16M Series A funding round, led by Playground Global.

Neuronetics, Inc. announced the grand opening of NeuroStar® University in Charlotte, North Carolina, the transcranial magnetic stimulation industry’s first of its kind training facility.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has established a patient specific website: https://www.nethertonsyndromeclinicaltrials.com/, to facilitate patient awareness and participation in its ongoing clinical study evaluating QRX003 for the treatment of Netherton Syndrome.

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, announced a letter to shareholders.

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced it will present at the H.C. Wainwright 24th Annual Global Investment Conference in New York City at 11:00 am, ET, on September 14, 2022.

Study has reached extended enrollment target of 160 patients Top-line data read-out expected in Q4-22.

Edgewise Therapeutics, Inc., (NASDAQ: EWTX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering of $100 million of its common stock.